Published by Josh White on 24th July 2025
(Sharecast News) - AstraZeneca announced on Thursday that its investigational treatment 'gefurulimab' achieved statistically significant and clinically meaningful results in a phase three trial for generalised myasthenia gravis (gMG), a rare autoimmune neuromuscular disorder.
URL: http://www.digitallook.com/dl/news/story/35238538/...